On this page
DZIP1L
DAZ interacting zinc finger protein 1 like
DZIP1L encodes a protein critical for the structure and function of primary cilia, cellular antennae that are essential for kidney development and maintaining normal organ architecture. The DZIP1L gene provides instructions for making a protein that plays a fundamental role in building and maintaining primary cilia, hair-like projections on cell surfaces that act as sensory structures.
DZIP1L is located on the long (q) arm of chromosome 3, at band 3q22.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Available at Jeen Health
Clinical tests that include this
Overview
DZIP1L (DAZ interacting zinc finger protein 1 like) encodes a protein localised to the base of primary cilia, microscopic structures that extend from the surface of nearly all human cells. Primary cilia function as cellular sensors, detecting chemical signals and mechanical forces in the surrounding environment. The DZIP1L protein contributes to the assembly and maintenance of these organelles, particularly in kidney epithelial cells.
Pathogenic variants in DZIP1L are associated with autosomal recessive polycystic kidney disease, a condition characterised by the development of fluid-filled cysts in the kidneys. Because cilia play essential roles in multiple organ systems during development, disruption of DZIP1L can also affect other tissues. The gene belongs to a family of proteins involved in organising the transition zone at the ciliary base, a region that controls which proteins enter and exit the cilium.
Understanding DZIP1L function has broader implications for comprehending how cells communicate with their environment and how developmental programmes are coordinated across tissues. The protein represents one component of a complex molecular machinery that must function correctly for normal organ formation, particularly in the urinary system.
What the gene does
The DZIP1L protein localises to the transition zone of primary cilia, a specialised region at the ciliary base that serves as a selective barrier controlling protein traffic into and out of the cilium. This gatekeeper function is essential because the cilium contains a distinct set of proteins required for signal transduction, and maintaining this unique protein composition is critical for proper ciliary function.
At the molecular level, DZIP1L contributes to organising the transition zone's structural architecture through protein-protein interactions mediated by its zinc finger and coiled-coil domains. The protein participates in assembling multi-protein complexes that anchor to the ciliary membrane and coordinate with the underlying microtubule cytoskeleton. These interactions help establish the diffusion barrier that prevents cytoplasmic proteins from entering the cilium whilst allowing ciliary proteins to pass through.
In kidney epithelial cells, proper DZIP1L function is particularly important for maintaining the planar orientation of cilia along tubules. Research suggests that defects in ciliary orientation or structure can disrupt mechanosensory signalling pathways that normally regulate cell division and tubule diameter. When these pathways malfunction, epithelial cells may proliferate abnormally and tubules may dilate, eventually forming the cysts characteristic of polycystic kidney disease.
The protein also appears to influence canonical Wnt signalling pathways and other developmental signalling cascades that depend on ciliary function. During embryonic kidney development, coordinated ciliary signalling helps orchestrate the branching morphogenesis of collecting ducts and the differentiation of nephron segments. DZIP1L dysfunction can therefore have cascading effects on multiple aspects of kidney architecture.
Beyond the kidney, DZIP1L expression in other ciliated tissues suggests roles in additional developmental processes. The transition zone complexes containing DZIP1L must assemble correctly in diverse cell types, from neural progenitors to airway epithelium, indicating that the protein's organisational functions are broadly conserved across different biological contexts.
Video: Genetics 101
Chromosome location
DZIP1L is located on the long arm of chromosome 3 at position 22.3 (3q22.3). This chromosomal region spans approximately 135 million base pairs from the centromere and contains numerous genes involved in developmental processes and cellular signalling.
The DZIP1L gene itself extends across genomic DNA and is transcribed to produce messenger RNA that encodes a 767-amino-acid protein. The gene's position places it within a chromosomal neighbourhood containing other genes relevant to epithelial cell function and organ development. Regulatory elements surrounding the gene likely control its expression in ciliated tissues during embryogenesis and in adult organs where cilia continue to play important roles, such as the kidney and reproductive tract.
Protein structure
The DZIP1L protein comprises 767 amino acids organised into several distinct structural features. Near the N-terminus, the protein contains a C2H2-type zinc finger domain spanning amino acids 166-189. Zinc finger domains typically mediate interactions with DNA or other proteins, and in DZIP1L this module likely contributes to the protein's ability to participate in multi-protein complexes at the ciliary base.
The central portion of the protein features an extended coiled-coil region from amino acids 205-406. Coiled-coil domains consist of alpha-helical structures that wind around each other, forming rope-like assemblies. These domains commonly mediate protein-protein interactions and are well suited for scaffolding functions. In DZIP1L, the coiled-coil region is predicted to facilitate interactions with other transition zone components, helping to organise the structural framework that controls ciliary access.
Two substantial disordered regions are present in the protein: amino acids 122-144 and a particularly long stretch from amino acids 518-767 extending to the C-terminus. Intrinsically disordered regions lack stable three-dimensional structure under physiological conditions but often serve important regulatory functions. These regions can undergo conformational changes in response to binding partners or post-translational modifications, providing flexibility in how the protein interacts with other ciliary components. The extensive C-terminal disordered region may allow DZIP1L to adapt its conformation to different molecular contexts at the transition zone, potentially facilitating dynamic assembly and remodelling of the ciliary gate structure.
Key variants
Pathogenic variants in DZIP1L follow an autosomal recessive inheritance pattern, meaning that affected individuals typically carry biallelic variants (changes in both gene copies). Carriers with a single pathogenic variant generally do not develop symptoms but can transmit the altered gene to their children.
The spectrum of DZIP1L variants includes loss-of-function changes such as nonsense mutations that introduce premature stop codons, frameshift variants resulting from small insertions or deletions, and splice-site alterations that disrupt normal messenger RNA processing. Missense variants, which change single amino acids, may also be pathogenic if they disrupt critical functional domains or protein stability. Variants affecting the zinc finger or coiled-coil domains are of particular interest because these regions are important for the protein's interactions at the ciliary transition zone.
Genotype-phenotype correlations are emerging as more affected families are identified. The severity of kidney disease and the presence of additional developmental features may relate to the specific nature of the variants and whether any residual protein function remains. Complete loss of DZIP1L function appears to result in more severe phenotypes during development.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
g.(?_137796321)_(137796494_?)del | - | Pathogenic | ★☆☆☆ | not provided |
c.1072G>T | p.Glu358Ter | Pathogenic | ★☆☆☆ | not provided |
c.1118del | p.Ala373fs | Pathogenic | ★☆☆☆ | not provided |
c.2002G>T | p.Gly668Ter | Pathogenic | ★☆☆☆ | not provided |
c.288C>A | p.Tyr96Ter | Pathogenic | ★☆☆☆ | not provided |
c.463C>T | p.Gln155Ter | Pathogenic | ★☆☆☆ | Polycystic kidney disease 5 |
c.857_858del | p.Ser286fs | Pathogenic | ★☆☆☆ | not provided |
c.925C>T | p.Arg309Ter | Pathogenic | ★☆☆☆ | not provided |
c.1061_1062del | p.Glu354fs | Pathogenic | - | Polycystic kidney disease 5 |
c.802_805del | p.Asp268fs | Pathogenic | - | DZIP1L-related disorder |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in DZIP1L cause polycystic kidney disease, an autosomal recessive condition characterised by the progressive development of fluid-filled cysts in the kidneys. The cysts arise from defects in the development and maintenance of kidney tubule architecture, resulting from impaired ciliary function in renal epithelial cells.
Affected individuals may present with kidney abnormalities detected during prenatal ultrasound screening or may develop symptoms in infancy or early childhood. Clinical features typically include enlarged kidneys with multiple cysts, progressive decline in kidney function, and in some cases accompanying developmental anomalies in other organ systems. The condition reflects the fundamental importance of primary cilia in coordinating kidney development and maintaining normal tubule diameter throughout life.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic DZIP1L variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
Within the NHS Genomic Medicine Service, DZIP1L has been classified on two gene panels that guide diagnostic testing. The gene holds green (high evidence) status on the Cystic Kidney Disease panel, reflecting substantial evidence linking biallelic DZIP1L variants to polycystic kidney phenotypes. It also appears with green classification (at level R21, indicating confident inclusion for relevant phenotypes) on the Fetal Anomalies panel, acknowledging that DZIP1L-related kidney abnormalities may be detected during prenatal imaging.
These panel inclusions mean that when clinicians in England request genetic testing for patients with cystic kidney disease or relevant foetal anomalies, DZIP1L will be among the genes analysed in accredited NHS laboratories. The green evidence level indicates that pathogenicity of DZIP1L variants in these contexts is well established, supporting confident clinical interpretation of test results.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with DZIP1L-related polycystic kidney disease, general kidney health principles observed in broader populations with kidney conditions may be relevant. Research in various forms of kidney disease suggests that maintaining adequate hydration supports kidney function, though specific fluid targets should be discussed with a nephrologist based on individual kidney function and any fluid restrictions that may apply.
Dietary considerations often focus on managing blood pressure and reducing kidney workload. Some studies in kidney disease populations indicate that moderating sodium intake may help control blood pressure and slow disease progression. Protein intake is another consideration; whilst adequate protein is essential for health, excessive protein consumption may increase metabolic demands on compromised kidneys. A renal dietitian can provide personalised guidance based on kidney function tests and nutritional requirements.
Blood pressure management is particularly important in polycystic kidney disease, as hypertension commonly develops and can accelerate decline in kidney function. Lifestyle measures that support healthy blood pressure in the general population-including regular physical activity appropriate to individual ability, maintaining a healthy weight, and stress management-may form part of a comprehensive care approach. However, specific targets and interventions should be determined by healthcare providers based on individual circumstances.
Regular monitoring of kidney function through blood tests and imaging allows healthcare teams to detect changes early and adjust management strategies. Families affected by DZIP1L variants should work closely with nephrology specialists who can tailor recommendations to the specific stage and manifestations of kidney disease in each individual.
Supplement considerations
There is currently no conclusive evidence that dietary supplements can prevent or reverse the kidney abnormalities caused by DZIP1L variants. The fundamental issue in DZIP1L-related polycystic kidney disease involves structural defects in ciliary function that affect cellular organisation during development, and nutritional supplements cannot correct these underlying cellular mechanisms.
Some individuals with kidney disease develop deficiencies in certain nutrients as kidney function declines. For example, reduced kidney function can affect vitamin D activation and lead to abnormalities in calcium and phosphate metabolism. In such cases, healthcare providers may recommend specific supplementation based on blood test results. However, these supplements address secondary complications of kidney disease rather than the primary genetic defect.
Certain supplements require particular caution in the context of kidney disease. High-dose vitamin C, for instance, can be converted to oxalate, which may accumulate when kidney function is impaired. Similarly, some herbal supplements can interact with medications or affect kidney function directly. Over-the-counter supplements marketed for general kidney health have not been rigorously tested in populations with genetic forms of polycystic kidney disease.
Anyone with DZIP1L-related kidney disease considering supplements should discuss this with their nephrologist or a registered dietitian familiar with kidney disease before taking any products. Healthcare providers can assess kidney function, review potential interactions with prescribed medications, and determine whether specific deficiencies warrant targeted supplementation based on biochemical testing.
Frequently asked questions
What inheritance pattern does DZIP1L follow?
DZIP1L-related conditions follow an autosomal recessive inheritance pattern. This means an individual must inherit a pathogenic variant from both parents to develop the associated kidney disease. Parents who each carry one variant are typically unaffected but have a 25% chance with each pregnancy of having an affected child.
How do DZIP1L variants cause kidney cysts?
DZIP1L variants impair the function of primary cilia, cellular structures that act as sensors on kidney epithelial cells. When cilia cannot function properly due to transition zone defects, the cells lose normal mechanosensory signalling and control over cell division. This leads kidney tubules to dilate abnormally and form fluid-filled cysts that progressively compromise kidney function.
Can DZIP1L variants be detected through standard genetic testing?
Yes, DZIP1L variants can be identified through genetic sequencing tests that examine genes associated with cystic kidney disease. In the NHS, DZIP1L is included on diagnostic gene panels for cystic kidney disease and foetal anomalies, meaning it will be analysed when clinicians request testing for these indications through NHS laboratories.
Are there treatments for DZIP1L-related kidney disease?
Management focuses on supporting kidney function and treating complications. This typically includes blood pressure control, monitoring kidney function through regular testing, managing any electrolyte imbalances, and addressing symptoms as they arise. In cases of advanced kidney failure, dialysis or kidney transplantation may be necessary. Treatment plans are individualised based on disease severity and progression.
Do all individuals with DZIP1L variants develop kidney problems?
Individuals with biallelic pathogenic variants (changes in both gene copies) typically develop kidney abnormalities, though the age of onset and severity can vary. Carriers with only one pathogenic variant generally do not develop kidney disease themselves. The specific variants involved and other genetic or environmental factors may influence disease expression.
What is the ciliary transition zone where DZIP1L functions?
The transition zone is a specialised region at the base of primary cilia that acts as a selective gate, controlling which proteins can enter the cilium. DZIP1L helps organise the molecular complexes that form this gate, ensuring the cilium maintains its unique protein composition necessary for proper sensory function. Defects in this gatekeeper function disrupt ciliary signalling in kidney cells.